Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
CVS Health director reported an automatic share disposal related to equity compensation. On 11/30/2025, 9,748 shares of CVS Health common stock were surrendered at a price of $80.36 per share under transaction code "F," which indicates shares withheld to cover taxes on a vesting restricted stock unit award.
After this tax-withholding transaction, the reporting person beneficially owned 19,438.4534 CVS Health shares, held directly. This filing reflects administrative handling of equity award taxation rather than an open-market sale initiated for investment reasons.
CVS Health Corp executive Heidi B. Capozzi reported a tax-related share withholding transaction. On 11/30/2025, she surrendered 9,470 shares of CVS Health common stock at $80.36 per share, coded as an "F" transaction, meaning the shares were withheld to cover taxes due on the vesting and settlement of a restricted stock unit award.
After this transaction, she directly owned 11,415 shares of CVS Health common stock as an executive vice president and Chief People Officer. This event reflects administrative handling of equity compensation rather than an open-market sale.
CVS Health Corp (CVS) director Douglas H. Shulman reported a routine equity compensation transaction. On 11/20/2025, he acquired 1,652 shares of common stock at a price of $76.04 per share, recorded as an "A" (acquired) transaction.
These shares were issued as payment of a semi-annual retainer at the market price under the company’s 2017 Incentive Compensation Plan, reflecting standard board compensation rather than an open-market purchase. Following this grant, Shulman beneficially owns 5,929 shares of CVS Health common stock in direct ownership.
CVS Health Corporation director Guy P. Sansone reported receiving common stock as part of his board compensation. On 11/20/2025, he acquired 1,652 shares of CVS common stock at a price of $76.04 per share. The filing explains this stock was issued as payment of a semi-annual retainer at market price under the company’s 2017 Incentive Compensation Plan. Following this grant, Sansone beneficially owns 13,659.355 shares of CVS common stock in direct ownership.
CVS Health Corp (CVS) reported a routine insider equity transaction by a non-employee director on a Form 4. On 11/20/2025, the director acquired 2,202.788 deferred stock units with a conversion price of $0 under the company’s 2017 Incentive Compensation Plan. These units were issued in connection with the deferral of a semi-annual retainer under the non-employee director compensation policy and are valued at the market price of $76.04 per underlying share of common stock. Each deferred stock unit will convert into one share of CVS common stock and will be issued when the director retires from the Board, as previously elected. Following this transaction, the director beneficially owns 8,080.2915 deferred stock units in direct form.
CVS Health (CVS) director equity grant reported
A CVS Health Corp director filed a Form 4 reporting receipt of 1,652 shares of common stock on 11/20/2025 at a price of $76.04 per share. These shares were issued as payment of a semi-annual board retainer at market price under the company’s 2017 Incentive Compensation Plan, meaning they represent routine director compensation in stock rather than cash.
Following this grant, the director beneficially owns 5,929 CVS common shares, held directly. The filing indicates this was a standard compensation-related issuance, not an open-market purchase or sale.
CVS Health Corp director reports deferred stock unit grant. A CVS Health Corp non-employee director filed a Form 4 reporting receipt of 2,021.9621 deferred stock units on 11/20/2025 under the company’s 2017 Incentive Compensation Plan. These units were issued in connection with the deferral of a semi-annual director retainer and valued at the market price of $76.04 per deferred stock unit.
Each deferred stock unit is to be converted into one share of CVS common stock and issued in the future, as elected by the reporting person. After this transaction, the director beneficially owns 4,613.3964 deferred stock units in direct form, reflecting accumulated deferred equity compensation rather than an open-market purchase or sale.
CVS Health (CVS) director J. Scott Kirby reported the receipt of additional company stock. On 11/20/2025, he acquired 1,652 shares of CVS Health common stock at a price of $76.04 per share. This was issued as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, rather than a market purchase.
Following this transaction, Kirby beneficially owns 12,987 CVS Health common shares, held directly. The filing is made on Form 4 as he serves as a director of CVS Health and is required to report changes in his ownership of company equity.
CVS Health director equity activity: A CVS Health Corp director reported routine equity compensation on a Form 4 for 11/20/2025. The director acquired 591 shares of common stock at $76.04 per share, which were issued as payment of a semi-annual cash retainer under the company’s 2017 Incentive Compensation Plan.
The filing also shows an award of 1,775.3814 deferred stock units, representing deferral of a semi-annual retainer under the non-employee director compensation policy. After this transaction, the director holds 16,530.0615 deferred stock units, each convertible into one share of CVS common stock to be issued in the future as elected by the director.
CVS Health reported a Form 4 for a director reflecting routine equity compensation. On 11/20/2025, the director acquired 1,652.091 deferred stock units with each unit representing one share of CVS Health common stock. These units were issued for deferral of a semi-annual retainer under the company’s non-employee director compensation policy and were valued at the market price pursuant to the 2017 Incentive Compensation Plan. After this transaction, the director beneficially owned 40,053.5157 deferred stock units on a direct basis.